mRNA

Eli Lilly’s bebtelovimab is the only authorized monoclonal antibody that can neutralize all three dominant sub-variants, investigators say.

COVID-19 vaccines will continue to protect the public against a spinoff omicron gene variant that’s making inroads across the United States, new data from the United Kingdom suggest.

Adults who receive a third dose of the Pfizer-BioNTech or Moderna vaccine are better protected against COVID-19 hospitalization than their peers who have received only two doses, and immunocompromised...

Pfizer and BioNTech plan to speed development of a prospective shingles drug, with clinical trials expected to begin in the second half of 2022. 

Among U.S. veterans, VE was 86 percent for Moderna and 75 percent for PfizerBioNTech vaccines at ≥120 days after the second dose

Second study shows reduction in rate of death due to COVID-19 with booster dose of BNT162b2

An FDA advisory panel has unanimously recommended approving COVID-19 booster shots for adults aged 65 years and older and for individuals at high risk of severe disease, including healthcare workers.

A study in nearly 1,000 healthcare workers has pinpointed factors that may boost the odds of having a reaction to a COVID-19 mRNA vaccine.

Dental, hearing, vision coverage on ‘front burner’ as lawmakers eye Medicare expansion … CDC: Pregnant women should get vaccinated; SARS-CoV-2 infection linked to preterm births … European drug...

The CDC has recommended that people who have a reaction to the Pfizer or Moderna vaccines take the Johnson & Johnson vaccine as a second shot. But the new study suggests that this “mixed” series of...